Nasdaq Panel Grants Marpai's Request For Extension To Comply With Continued Listing Requirements
Nasdaq Panel Grants Marpai's Request For Extension To Comply With Continued Listing Requirements
Marpai, Inc. ("Marpai" or the "Company") (NASDAQ:MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced that it received notice from the Nasdaq Hearings Panel ("Panel") of The Nasdaq Stock Market ("Nasdaq") that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market (the "Panel Decision"), as discussed more fully below.
Marpai, Inc.（“Marpai” 或 “公司”）（納斯達克股票代碼：MRAI）是一家獨立的國家第三方管理局（TPA）公司，該公司正在改造220億美元的TPA市場，爲自籌資金的僱主健康計劃提供負擔得起、智能的醫療保健計劃。該公司今天宣佈，它已收到納斯達克股票市場（“納斯達克”）納斯達克聽證小組（“小組”）的通知，已批准公司延期，以恢復對持續遵守規定的合規性納斯達克資本市場的上市要求（“小組決定”），詳見下文。
Subject to the Company meeting certain requirements by March 31, 2024, the Hearings Panel granted the Company an extension until May 28, 2024, to regain compliance with the Market Value of Listed Securities ("MVLS") requirement of $35,000,000 or satisfy any of the alternative requirements in Listing Rule 5550(b).
在公司在2024年3月31日之前滿足某些要求的前提下，聽證會小組批准公司延期至2024年5月28日，以恢復遵守35,000,000美元的上市證券市值（“MVLS”）要求或滿足《上市規則》第5550（b）條中的任何替代要求。
譯文內容由第三人軟體翻譯。